BACKGROUND: The current study evaluated factors influencing survival in patients diagnosed with human immunodeficiency virus (HIV)-related primary central nervous system lymphoma (PCNSL), with a focus on the effects o...BACKGROUND: The current study evaluated factors influencing survival in patients diagnosed with human immunodeficiency virus (HIV)-related primary central nervous system lymphoma (PCNSL), with a focus on the effects of therapeutic radiotherapy (RT) and highly active antiretroviral therapy (HAART). METHODS: A retrospective chart review of patients with a diagnosis of HIV-related PCNSL at one of five university hospitals between 1987 and 1998 was performed. Clinical details including antiretroviral agent use, brain imaging scan results, RT use, and survival outcomes were recorded. RESULTS: One hundred eleven patients with HIV-related PCNSL were identified. The annual incidence decreased significantly between 1992 and 1995 and between 1996 and 1998 (P=0.04).展开更多
Background/Aims:Risks of hepatocellular carcinoma(HCC) following hepatitis B and/or hepatitis C virus(HBV/HCV) infection are well known,those for other cancers are less well understood.The aim was to quantify the risk...Background/Aims:Risks of hepatocellular carcinoma(HCC) following hepatitis B and/or hepatitis C virus(HBV/HCV) infection are well known,those for other cancers are less well understood.The aim was to quantify the risk of cancers among persons diagnosed with HBV/HCV infections.Methods:The data from a cohort of 39109 HBV,75834 HCV,and 2604 HBV/HCV co-infected persons notified to the State health department,1990-2002,were probabilistically linked to the Cancer Registry and standardised incidence ratios(SIRs) for cancer were calculated.Results:The match rate for any cancer was 2.7%,2.3% and 3.3% for HBV,HCV and HBV/HCV co-infected notifications.SIRs for HCC were 30.6(95% CI 25.7-36.5) ,22.7(95% CI 19.1-26.5) and 30.3(95% CI 13.6-67.5) ,respectively.Increased risk was detected for Burkitt’s lymphoma and HBV(SIR 12.9,95% CI 5.4-30.9) and immunoproliferative malignancies following HCV(SIR 5.6,95% CI 1.8-17.5) .Conclusions:The risk of HCC in the infected cohort was 20-30 times greater than in the uninfected population with SIRs two to three times greater than those for the other HBV/HCV infection associated cancers.The modest though significant risk of immunoproliferative malignancies associated with HCV infection is consistent with recent findings.展开更多
文摘BACKGROUND: The current study evaluated factors influencing survival in patients diagnosed with human immunodeficiency virus (HIV)-related primary central nervous system lymphoma (PCNSL), with a focus on the effects of therapeutic radiotherapy (RT) and highly active antiretroviral therapy (HAART). METHODS: A retrospective chart review of patients with a diagnosis of HIV-related PCNSL at one of five university hospitals between 1987 and 1998 was performed. Clinical details including antiretroviral agent use, brain imaging scan results, RT use, and survival outcomes were recorded. RESULTS: One hundred eleven patients with HIV-related PCNSL were identified. The annual incidence decreased significantly between 1992 and 1995 and between 1996 and 1998 (P=0.04).
文摘Background/Aims:Risks of hepatocellular carcinoma(HCC) following hepatitis B and/or hepatitis C virus(HBV/HCV) infection are well known,those for other cancers are less well understood.The aim was to quantify the risk of cancers among persons diagnosed with HBV/HCV infections.Methods:The data from a cohort of 39109 HBV,75834 HCV,and 2604 HBV/HCV co-infected persons notified to the State health department,1990-2002,were probabilistically linked to the Cancer Registry and standardised incidence ratios(SIRs) for cancer were calculated.Results:The match rate for any cancer was 2.7%,2.3% and 3.3% for HBV,HCV and HBV/HCV co-infected notifications.SIRs for HCC were 30.6(95% CI 25.7-36.5) ,22.7(95% CI 19.1-26.5) and 30.3(95% CI 13.6-67.5) ,respectively.Increased risk was detected for Burkitt’s lymphoma and HBV(SIR 12.9,95% CI 5.4-30.9) and immunoproliferative malignancies following HCV(SIR 5.6,95% CI 1.8-17.5) .Conclusions:The risk of HCC in the infected cohort was 20-30 times greater than in the uninfected population with SIRs two to three times greater than those for the other HBV/HCV infection associated cancers.The modest though significant risk of immunoproliferative malignancies associated with HCV infection is consistent with recent findings.
